Canna~Fangled Abstracts

Therapy Insight: bladder dysfunction associated with multiple sclerosis.

By November 5, 2013No Comments

pub med big

Source

National Hospital for Neurology and Neurosurgery, Queen Square, London, UK.

Abstract

Bladder dysfunction is a common problem for patients with multiple sclerosis. The severity of symptoms often correlate with the degree of spinal cord involvement and, hence, the patient’s general level of disability. The emphasis of management is now mainly medical and is increasingly offered by nonurologists. Treatments can be highly effective, relieving patients of what are otherwise very troublesome symptoms that would compound their neurological disability. This article gives an overview of the neural control of the bladder, followed by an explanation of the pathophysiology of detrusor overactivity secondary to neurological disease. A review of methods available for treating bladder dysfunction in multiple sclerosis then follows. The treatment options for this disorder are largely medical and include established first-line measures such as anticholinergics, clean intermittent self-catheterization and the use of desmopressin, as well as potential second-line agents, such as cannabinoids, intravesical vanilloids and intradetrusor botulinum neurotoxin type A. The diminishing role of surgical intervention is also discussed.
PMID:
16474623
[PubMed – indexed for MEDLINE]

Publication Types, MeSH Terms

REVIEW CRITERIA

PubMed was searched for articles published from January 1965 to March 2005 using the terms “multiple sclerosis”, “bladder”, and “incontinence”. Additional papers were also obtained from the bibliographies of selected articles. The selection of papers was based on relevance on subject matter, clinical importance and scientific value.

Topof page

INTRODUCTION

PM thumb siteThe estimated prevalence of urogenital symptoms in multiple sclerosis (MS) has varied, depending on the populations studied. Estimates of between 52% and 97% have been cited,1 but, since these problems result mainly from spinal cord involvement,2, 3 figures that show an occurrence similar to that of lower limb dysfunction (75%)4 or to the MRI estimate of incidence of spinal cord lesions (74%)5 seem more realistic. There is a clear gender difference in the prevalence of MS, with females being more commonly affected than males, on average by a ratio of 2:1.6 The nature of micturition complaints and lower urinary tract symptoms also differ between sexes. Obstruction complaints, such as hesitation, interrupted or weak urine flow and incomplete emptying, are found more frequently in men, whereas incontinence complaints (involuntary loss of urine) are more frequent in women. Irritative complaints of urgency, frequency, nocturia and pain are found equally between sexes.7Urogenital symptoms in patients with MS are therefore common, and are clearly recognized to have significant adverse effects on the quality of life of this group of patients.8, 9 Fortunately, this is an area where therapeutic intervention can be highly effective, as will be described in this review.

Topof page

NEUROLOGICAL CONTROL OF THE BLADDER

Functional brain imaging studies are adding to our understanding of the contribution of higher centers and signal processing involved in bladder control, so that voiding can be achieved in a socially appropriate time and place. Such studies have shown that a complex of brain networks is involved in the two processes of bladder storage10, 11 and voiding,12, 13 but that the final result of these processes is either activation or inhibition of the pontine micturition center (PMC). Direct pathways from the PMC project to the sacral segments of the spinal cord (S2–S4) (Figure 1), and determine parasympathetic outflow to the detrusor and reciprocal activity of the motor neurons innervating the striated urethral sphincter.14

Figure 1 Illustration of the pathways involved in micturition.

Figure 1 : Illustration of the pathways involved in micturition. Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.comPAG, periaqueductal gray; PMC, pontine micturition center.
Full figure and legend (67K)Figures & Tables indexDownload PowerPoint slide (280K)

Whilst in the storage phase, detrusor pressure does not rise. This is because the bladder fills as a result of inhibition of parasympathetic innervation of the detrusor, and pressure within the urethra is maintained at a higher level than within the bladder by tonic firing of the motor units of the striated urethral sphincter and pelvic floor. At the initiation of micturition there is relaxation of the striated urethral sphincter and pelvic floor, followed by a coordinated contraction of the detrusor muscle. This synergistic activity between the sphincter and the detrusor is dependent on connections with the pontine region. A condition known as ‘detrusor sphincter dyssynergia’ (DSD) might arise if these connections are damaged or interrupted, resulting in sphincter contraction as the detrusor contracts.15
The most marked abnormality occurs as a consequence of disconnection of sacral segments from the PMC. This results in the emergence of a segmental reflex that causes detrusor contractions in response to bladder distension. Evidence from animal experiments and human studies show that, following any form of spinal cord lesion, unmyelinated C fibers that were formally quiescent (and therefore known as ‘silent C fibers’) become mechanosensitive and respond to bladder stretch.16 Detrusor contractions are caused by this afferent activity, through synaptic activity in the sacral segment of the cord.17It is this process that is responsible for detrusor overactivity, the pathophysiology underlying the common complaints of urinary frequency, urgency and urgency incontinence, referred to collectively as overactive bladder syndrome.18, 19
Abnormal urodynamic findings in patients with dysfunctional voiding symptoms and MS are common, as shown by a meta-analysis of 1,900 patients.1 Table 1summarizes the incidences of the major patterns of urodynamic dysfunction reported in patients with MS. Detrusor hyperreflexia, the most common urodynamic abnormality in MS, is now referred to as ‘neurogenic detrusor overactivity’, following recent changes in the nomenclature.19 Since a relapsing and remitting, or more commonly progressive, clinical course is a characteristic of MS, the lower urinary tract symptoms might also worsen, and regular reviews of bladder status have been recommended.20, 21

Table 1 Summary of urodynamic abnormalities found in patients with multiple sclerosis.

Table 1 - Summary of urodynamic abnormalities found in patients with multiple sclerosis.
Full tableFigures & Tables indexDownload PowerPoint slide (282K)

The worsening of bladder dysfunction with increasing spinal cord involvement in MS has been clinically demonstrated in a number of studies.2, 7, 22 Imaging studies using MRI have reported a correlation between urologic complaints and spinal cord cross-sectional area, which is used as a marker for spinal cord atrophy,23 yet there is little evidence for the association between urinary symptoms and brain MRI parameters.24, 25
As the neurological condition progresses, the bladder dysfunction can become more difficult to treat. This can be attributed to worsening of detrusor overactivity, inefficient emptying of the bladder in the context of worsening paraparesis, recurrent urinary tract infections, spasticity, reduction in general mobility, and sometimes cognitive impairment. In contrast to urinary tract dysfunction following traumatic spinal cord injury, progressive neurological diseases rarely cause upper urinary tract involvement.7, 26 This is true even when longstanding MS has resulted in severe disability and spasticity. Although the reason behind this difference in action is unknown, the evidence implies that the focus of management should be on symptomatic relief. The pathophysiologic changes that occur in MS and their symptomatic consequences lead to detrusor overactivity and detrusor sphincter dyssynergia, resulting in incomplete bladder emptying.

Topof page

MANAGEMENT OF LOWER URINARY TRACT SYMPTOMS IN MULTIPLE SCLEROSIS

FIRST-LINE TREATMENTS

Anticholinergic medication
Anticholinergic agents are a logical first treatment choice for patients with MS presenting with neurological bladder dysfunction, as the most common symptoms are caused by detrusor overactivity.2 The majority of muscarinic receptors expressed in the detrusor muscle are M2;27, 28 however, the functionally important receptors in the detrusor muscle are the M3 receptors, as these maintain normal bladder function.27, 29 The benefit of selective blockade of M2 or M3 muscarinic receptors, including the possible advantage of not affecting brain M1 receptors, has yet to be translated into clinical effect.
A number of antimuscarinic agents, some of them only recently licensed in the UK, are available to treat symptoms of detrusor overactivity (Table 2). The long-acting (extended-life [‘XL’]) formulation of these medications gives a significant advantage to patients, who need only take the tablet once a day to provide 24-hour cover for symptoms. The chemical structure of the antimuscarinic agents tolterodine and trospium renders them less lipophilic and, therefore, theoretically less likely to cross the blood–brain barrier than other antimuscarinic agents, resulting in fewer CENTRAL ADVERSE EFFECTS.30,31 These drugs might therefore have particular benefit for patients with cognitive impairment.

Table 2 Anticholinergic agents used to treat symptoms of detrusor overactivity.

Table 2 - Anticholinergic agents used to treat symptoms of detrusor overactivity.
Full tableFigures & Tables indexDownload PowerPoint slide (312K)

Prior to prescribing an anticholinergic for patients complaining predominantly of symptoms of detrusor overactivity, it is important to measure their postvoid residual (PVR) urine volume.32, 33 This is particularly important if the patient’s symptoms indicate that there is a component of incomplete voiding. The PVR urine volume can now be conveniently measured using a small hand-held ultrasound device (Figure 2), to which many specialist nurse continence advisors and MS clinic nurses now have access, allowing them to conduct these examinations. The importance of recognizing incomplete emptying is that any residual volume in the bladder can trigger volume-determined reflex detrusor contractions, exacerbating the clinical situation through worsening of the symptoms of frequency, urgency and urgency incontinence.34

Often patients cannot gauge the extent to which they have incomplete bladder emptying, but it has been shown that those who suspect that they have this problem are often correct.2 It is therefore important to ask patients whether they have a sensation of incomplete bladder emptying or if they are able to pass the same amount of urine at a second void only minutes after the first, as these points are strong indicators that a high PVR volume could be contributing to their bladder problems.
Complex management and investigation protocols, such as the Clinical Practice Guidelines for the Multiple Sclerosis Council,35 have been proposed for bladder dysfunction and MS. Figure 3 shows a simple algorithm based on two main interventions (medication with anticholinergics and intermittent catheterization) for the initial management of the most common symptoms of bladder dysfunction in MS. Although there has yet to be a controlled study into the efficacy of this algorithm, it has provided a convenient, low-cost management scheme, and has been used daily in the authors’ department for 15 years. The role of cystometry and video cystometry in the investigation of patients with MS has been promoted by some authors, because it is only through these investigations that DSD can be diagnosed.15, 36, 37 Since there is no definitive treatment for DSD, however, other than managing the resulting incomplete bladder emptying and raised detrusor pressure, a pragmatic approach would recommend the use of cystometry and video cystometry.

Figure 3 Algorithm for the management of neurogenic incontinence.

Figure 3 : Algorithm for the management of neurogenic incontinence. Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.comReproduced with permission from reference 33 © (1996) Blackwell Publishing Ltd. CISC, clean intermittent self-catheterization; PVR, postvoid residual urine.
Full figure and legend (40K)Figures & Tables indexDownload PowerPoint slide (242K)

Conservative measures to improve bladder emptying
Reduction of a raised PVR volume is necessary to improve symptoms. This can be achieved by the patient, or sometimes by their caregiver, through clean intermittent self-catheterization (CISC). If a symptomatic patient has a PVR volume of over 100 ml, CISC is advocated. Important considerations when deciding whether patients are appropriate for this intervention include their motivation, whether they have good cognitive skills and adequate manual dexterity, and their overall physical status.
Unfortunately, there are few other proven methods for improving bladder emptying. There have been claims that alpha-blockers can reduce PVR volumes,38,39 although this has not been confirmed by other studies. The clinical impression that alpha-blockers are effective in individual patients is not strong, possibly because incomplete bladder emptying in patients with MS is thought to be the result of a combination of poorly sustained and ill-coordinated detrusor contractions, or of an inappropriate contraction of the striated urethral sphincter, a muscle on which alpha-blockers are thought to be ineffective.40
The application of a suprapubic vibrating stimulus is the only other proven means of improving bladder emptying, and is a method that has benefited some patients.41, 42 In patients with REFLEX DETRUSOR OVERACTIVITY, the vibrating stimulus might help to initiate micturition and possibly improve bladder emptying by triggering a detrusor contraction; these results might not be seen when intact innervation is present, however. Several devices are commercially available for suprapubic vibration, including small hand-held, battery-operated vibrators.42, 43
Desmopressin
The synthetic antidiuretic hormone desmopressin (DDAVP®, Rhone-Poulenc Rorer Pharmaceuticals Inc., Collegeville, PA), was originally licensed to treat the polyuria of DIABETES INSIPIDUS. Having become an established treatment for nocturnal enuresis,44 its efficacy for the treatment of women with MS experiencing night-time frequency has been shown.45 Its effectiveness, if taken during the day, in providing patients with up to 6 hours during which they were untroubled by urinary frequency, without any rebound night-time frequency, has been demonstrated by a number of small studies.46, 47
Desmopressin (10–20 mug) should only be taken once in every 24-hour period, and should not be given to patients over 65 years of age, or used in patients with dependant leg edema resulting from immobility who have night-time frequency when recumbent. In spite of these precautions, a number of patients find that this drug can provide additional benefit to that conferred by the other first-line measures if they are looking to be reliably free of symptoms for a long journey or a particular social event.47

INDICATIONS FOR ADDITIONAL INVESTIGATIONS

The first-line treatments for lower urinary tract symptoms consist of oral anticholinergics with or without CISC, and many neurologists and neurorehabilitation physicians, with the help of continence advisors, can advise patients accordingly. Patients experiencing recurrent urinary tract infections, hematuria, or pain that is thought to originate from the upper or lower urinary tract, and those with evidence of impaired renal function, should be referred to a urologist.
In aging men with MS, an element of lower urinary tract symptoms might be attributable to benign prostatic hyperplasia (BPH).48 The challenge in these patients, therefore, is to establish to what extent the symptoms are due to BPH, and how they much they bother the patient. The degree to which the symptoms of BPH are bothersome will help to determine further management, which could include watchful waiting, medical, minimally invasive or surgical therapies. Initial evaluation of these patients should include a detailed medical history to identify the causes of voiding dysfunction, a physical examination, and both a digital rectal examination and a focused neurological examination. Following the evaluation, a urinary-flow-rate recording and measurement of the PVR might be helpful. Surgery is only recommended in patients who have renal insufficiency that is clearly due to BPH, and in those patients with recurrent urinary tract infections, recurrent gross hematuria, or bladder stones that are clearly due to BPH and refractory to other therapies.49 These patients should be referred to a urologist.

SECOND-LINE TREATMENTS FOR OVERACTIVE BLADDER SYNDROME

Undoubtedly there is a point in the progression of MS where first-line treatment might be insufficient to control urinary symptoms, and yet the patient does not want to have a long-term indwelling catheter (Figure 4). This point is often reached as patients’ neurological disability, especially their mobility, is deteriorating such that they are not in a sufficiently robust state to undergo major surgery (such as an augmentation cystoplasty). Various new nonsurgical and, at the time of writing, unlicensed treatment options are emerging for these patients.

Figure 4 The bladder symptoms in multiple sclerosis become increasingly difficult to manage with progression of spinal cord disease.

Figure 4 : The bladder symptoms in multiple sclerosis become increasingly difficult to manage with progression of spinal cord disease. Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.comThe various measures that might be effective at each stage are summarized here. ADH, antidiuretic hormone; BoNT/A, botulinum neurotoxin type A; buzzer, suprapubic vibrating stimulus; CBME, cannabis-based medical extract; CISC, clean intermittent self-catheterization; IDC, indwelling catheter.
Full figure and legend (55K)Figures & Tables indexDownload PowerPoint slide (262K)

Cannabinoids
The illegal use of cannabis by patients with MS has become common in the UK, to such an extent that a diagnosis of MS was sometimes debated as an extenuating argument by people found growing Cannabis sativa. In 1998, further exploration into the medicinal properties of cannabis was proposed by a high-level UK government report,50 resulting in a number of small-scale, open-label studies that examined the effect of medicinal cannabinoid extracts on patients with chronic pain or MS. Included in these trials was a small open-label study in patients with advanced MS, refractory to conventional treatments, and in whom having a long-term indwelling catheter was a looming prospect. The results of this pilot study demonstrated a significant decrease in urinary urgency and a reduction in the number and volume of incontinence episodes, as well as a reduction in frequency and nocturia. Daily total voided and catheterized volume, and urinary incontinence pad weights, were also significantly decreased, whilst patients reported significant improvements in spasticity, quality of sleep and level of pain (measured by patient self-assessment).51 Large, multicenter, randomized placebo-controlled trials are underway, although no results are available.
The Cannabis in Multiple Sclerosis (CAMS) study, a large, multicenter, placebo-controlled trial funded by the UK Medical Research Council, was established to look at the effect of oral nabilone and tetrahydrocannabinol (THC) on patients with MS. Although the study is ongoing, results so far have shown no change in the ASHWORTH SCALE SCORES (Table 3); however, the patients did report subjective improvements in spasticity.52 A subsidiary study looked at the effect of oral nabilone and THC on bladder symptoms and, although the data are only reported in an abstract, the results suggest that there is a lessening of urinary urgency and a reduced number of episodes of urge incontinence on active treatment.53 Whether or not this medication becomes a licensed therapy in the UK, or other countries, for the treatment of specific symptoms in MS such as spasticity and urinary urgency and frequency, is yet to be decided.

Table 3 The Ashworth Scale used as a clinical measure of spasticity.

Table 3 - The Ashworth Scale used as a clinical measure of spasticity.
Full tableFigures & Tables indexDownload PowerPoint slide (261K)

Intravesical vanilloids
The use of intravesical vanilloids to reduce the number of afferent nerve endings of the bladder was rationalized by the knowledge of the importance of the emergence of C-fiber reflex causing detrusor overactivity following a spinal cord lesion.16 Intravesical capsaicin was the first vanilloid to be used in patients with neurogenic detrusor overactivity.54 Although there is good evidence that intravesical capsaicin has a therapeutic effect,55 its use has been largely abandoned because it is not licensed and could cause considerable discomfort to patients when instilled. The prospect, therefore, of using intravesical resiniferatoxin (RTX®, Afferon Corporation, Scottsdale, AZ), an ultra-potent capsaicinoid56 that is thought to have the same neurotoxic effect on bladder afferents57 but is less pungent,58 was greeted with enthusiasm. Clinical trials have been hampered by the compound’s tendency to adhere to plastic, however. In the studies published, the number of patients in whom this treatment was effective was small.59 It now seems unlikely that a pharmaceutical company will market this medication in the future.
Further work with capsaicin has shown that its irritant effects can be reduced if glucidic acid, rather than 30% alcohol, is used as the diluting solution. A randomized controlled trial compared the efficacy and tolerability of capsaicin in glucidic acid and resiniferatoxin in 10% alcohol in patients with neurogenic bladder overactivity. The results revealed that the formulations were highly comparable in relieving symptoms of detrusor overactivity.60 Intravesical capsaicin is still offered as a treatment option in a neurorehabilitation and research center in Bordeaux, France.
Detrusor injections of botulinum neurotoxin type A
First described by Schürch et al. in 2000 for patients with spinal cord injuries, botulinum neurotoxin type A (BoNT/A) injected directly into the smooth muscle of the detrusor is having a major impact on the treatment of neurogenic detrusor overactivity.61, 62 Originally proposed on the basis that BoNT/A would merely paralyze the detrusor by blocking the presynaptic release of parasympathetic acetylcholine-mediating detrusor contraction, the benefits of this treatment appear to exceed those expected. It seems likely that BoNT/A also affects the vesicular release of neurotransmitters involved in the afferent arm of reflex bladder contractions; work on this is ongoing.63
In our own studies, a series of 31 patients with MS have received injections of 300 units of BoNT/A (Botox®, Allergan, Irvine, CA)64 using a minimally invasive local anesthetic outpatient technique, pioneered in our department.65Sparing the trigone, for reasons of tolerability and potential ureteric reflux, this technique involves injecting 30 equally spaced points in the bladder, using a flexible cystoscope and a superfine 27-gauge disposable needle that locks into a reusable sheath (Figure 5). Each injection is comprised of 10 units of Botox® (1 ml).

Figure 5 Injection sites using the minimally invasive outpatient technique.

Figure 5 : Injection sites using the minimally invasive outpatient technique. Unfortunately we are unable to provide accessible alternative text for this. If you require assistance to access this image, or to obtain a text description, please contact npg@nature.comA flexible cystoscope with a superfine 27-gauge disposable needle is used to inject BOTOX® (Allergan, Irvine, CA) into the bladder, avoiding the trigone. Each of the 30 different injections, containing 10 units of BOTOX® (1 ml), are introduced at equally spaced points.
Full figure and legend (48K)Figures & Tables indexDownload PowerPoint slide (248K)

Voiding-diary data are showing exceptional clinical efficacy for BoNT/A, with significant improvements compared to baseline of urinary urgency, frequency and incontinence episodes at 4 and 16 weeks postinjection. Urodynamic parameters, namely maximum cystometric capacity and detrusor pressures during filling, have also shown significant and sustained improvement.64Because there is an increased incidence in incomplete bladder emptying following treatment in patients with neurogenic bladder dysfunction, patients must be willing and able to perform CISC, if they are not already doing so.
Initial results of trials investigating repeated injections show similar beneficial effects and duration of treatment action for these and primary injections. Projected cost consequences are modest (UK£780 per annum per patient) compared with surgery or long-term anticholiergics or neuromodulation, with a median time of 13 months between injections.66 Cost-effectiveness studies comparing intradetrusor BoNT/A with anticholinergics, neuromodulation and surgery, are currently being set up. Although not yet licensed for this use, BoNT/A is emerging as an effective and popular second-line treatment for symptoms of neurogenic detrusor overactivity, which is increasingly being adopted by many urology, neurology and rehabilitation centers worldwide.
Surgical management
The advent of effective noninvasive treatments for patients with bladder dysfunction secondary to MS has caused surgical management techniques to take a lesser role. Denervation procedures, including selective posterior rhizotomy, subtrigonal injection of phenol or alcohol, bladder myotomy and transection, might have shown good short-term results, but long-term results have been much less satisfactory.67 Augmentation procedures of the bladder, such as augmentation cystoplasty (with or without a catheterizable limb), might allow large volumes of urine to be contained within the bladder at low pressures, but most patients need to perform CISC.68, 69 The ability to do so is often lost as the neurological condition of the patient deteriorates.
Sacral-nerve neuromodulation is being investigated in patients with MS, and a small study of nine patients with neurogenic detrusor overactivity, five of whom had MS, reported clinical and urodynamic improvement at 46 months follow-up.70 Longer follow-up and larger cohorts of patients with MS are needed to assess carefully the cost-effectiveness of this intervention.
Long-term indwelling catheter
There is a stage in the patient’s progression at which a long-term indwelling catheter becomes necessary. This is usually when the patient has become severely disabled, being unable to stand, or being chair-bound or even bed-bound. Cognitive impairment, lower-limb spasticity, and loss of manual dexterity, together with increasing detrusor overactivity, mean that CISC, even with the aid of a caregiver, is no longer feasible. In these cases an indwelling catheter is appropriate, and initially a urethral catheter connected to a leg bag will familiarize the patient and their carer with what is involved in indwelling catheterization. The urethral catheter should then ideally be promptly replaced by a suprapubic catheter.71 Long-term urethral catheters are not advisable because of the urethral trauma they commonly inflict.
Suprapubic catheters should ideally be sited by a urological surgeon, who might want to give the patient a general anesthetic so that the bladder can be distended to facilitate the suprapubic puncture into the otherwise shrunken bladder. Once the suprapubic tract has been epithelialized, usually 6–8 weeks post-puncture, the catheter can be changed for the first time. The first catheter change should ideally be performed under the care of a urology team; subsequent changes at intervals of 3 months can be carried out by district or practice nurses.

Topof page

CONCLUSION

MS and its associated bladder symptoms have a considerable negative impact on patients’ quality of life and, although progression of the neurological disease is proving difficult to halt, much can now be done to improve bladder control. Intermittent self-catheterization can make a crucial difference to management of patients in whom incomplete voiding is contributing to bladder dysfunction. The development of more selective oral agents is to be welcomed, as is the exciting discovery of intradetrusor botulinum neurotoxin injections to treat severely affected patients. Surgery has comparatively less to offer, and effective management is becoming possible largely as an outpatient procedure. Many patients’ bladder problems are now being managed in the same clinic as cares for their underlying neurological disease, although urologic invention might still be necessary to deal with stone formation, recurrent infections and placement of a suprapubic catheter.
Overall, the options for bladder management in MS have improved greatly, and more patients are able to receive effective treatment for very distressing symptoms that would otherwise compound their neurological disability.

REFERENCES

  1. Litwiller SE et al. (1999) Multiple sclerosis and the urologist. J Urol 161: 743–757 | Article | PubMed | ISI | ChemPort |
  2. Betts CD et al. (1993) Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry 56: 245–250 | PubMed | ISI | ChemPort |
  3. Hawker KS and Frohman EM (2001) Bladder, Bowel, and Sexual Dysfunction in Multiple Sclerosis. Curr Treat Options Neurol 3: 207–214 | PubMed |
  4. Miller H et al. (1965) Bladder Dysfunction in Multiple Sclerosis. Br Med J 5445: 1265–1269 | PubMed | ChemPort |
  5. Kidd DJ et al. (1993) Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 43: 2632–2637 | PubMed | ISI | ChemPort |
  6. Zivadinov R et al. (2003) The use of standardized incidence and prevalence rates in epidemiological studies on multiple sclerosis. A meta-analysis study.Neuroepidemiology 22: 65–74 | Article | PubMed | ISI |
  7. Koldewijn EL et al. (1995) Relationship between lower urinary tract abnormalities and disease-related parameters in multiple sclerosis. J Urol 154: 169–173 | PubMed | ISI | ChemPort |
  8. Nortvedt MW et al. (2001) Reduced quality of life among multiple sclerosis patients with sexual disturbance and bladder dysfunction. Mult Scler 7: 231–235 | Article | PubMed | ISI | ChemPort |
  9. Fernandez O (2002) Mechanisms and current treatments of urogenital dysfunction in multiple sclerosis J Neurol 249: 1–8 | PubMed | ISI |
  10. Athwal BS et al. (2001) Brain responses to changes in bladder volume and urge to void in healthy men. Brain 124: 369–377 | Article | PubMed | ISI | ChemPort |
  11. Matsuura S et al. (2002) Human brain region response to distention or cold stimulation of the bladder: a positron emission tomography study. J Urol 168: 2035–2039 | Article | PubMed | ISI |
  12. Blok BF et al. (1997) A PET study on brain control of micturition in humans. Brain120: 111–121 | Article | PubMed | ISI |
  13. Blok BF et al. (1998) Brain activation during micturition in women. Brain 121: 2033–2042 | Article | PubMed | ISI |
  14. Blok BF (2002) Central pathways controlling micturition and urinary continence.Urology 59 (Suppl 1): S13–S17 | Article |
  15. Blaivas JG and Barbalias GA (1984) Detrusor-external sphincter dyssynergia in men with multiple sclerosis: an ominous urologic condition. J Urol 131: 91–94 | PubMed | ISI | ChemPort |
  16. de Groat WC et al. (1990) Mechanisms underlying the recovery of urinary bladder function following spinal cord injury. J Auton Nerv Syst 30 (Suppl): S71–S77 | Article |
  17. Birder L et al. (1998) Adrenergic- and capsaicin-evoked nitric oxide release from urothelium and afferent nerves in urinary bladder. Am J Physiol 275: F226–F229 | PubMed | ISI | ChemPort |
  18. Andersson KE (2001) The basis for drug treatment of the overactive bladder.World J Urol 19: 294–298 | PubMed | ISI | ChemPort |
  19. Abrams PL et al. (2003) The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61: 37–49 | Article | PubMed | ISI |
  20. Wheeler JS Jr et al. (1983) The changing neurourologic pattern of multiple sclerosis. J Urol 130: 1123–1126 | PubMed | ISI |
  21. Ciancio SJ et al. (2001) Urodynamic pattern changes in multiple sclerosis. Urology57: 239–245 | Article | PubMed | ISI | ChemPort |
  22. Awad SA et al. (1984) Relationship between neurological and urological status in patients with multiple sclerosis. J Urol 132: 499–502 | PubMed | ISI | ChemPort |
  23. Lycklama A et al. (1998) Brain and Spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain 121: 687–697 | PubMed |
  24. Kim Y et al. (1998) The correlation of urodynamic findings with cranial magnetic resonance imaging findings in multiple sclerosis. J Urol 159: 972–976 | PubMed | ISI | ChemPort |
  25. Ukkonen M et al. (2004) Urodynamic findings in primary progressive multiple sclerosis are associated with increased volumes of plaques and atrophy in the central nervous system. Acta Neurol Scand 109: 100–105 | Article | PubMed | ISI | ChemPort |
  26. Sirls LT et al. (1994) Role of limited evaluation and aggressive medical management in multiple sclerosis: a review of 113 patients. J Urol 151: 946–950 | PubMed | ISI | ChemPort |
  27. Chess-Williams R et al. (2001) The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 21: 243–248 | Article | PubMed | ISI | ChemPort |
  28. Sigala S et al. (2002) Differential gene expression of cholinergic muscarinic receptor subtypes in male and female normal human urinary bladder. Urology 60: 719–725 | Article | PubMed | ISI |
  29. Harriss DR et al. (1995) Expression of muscarinic M3-receptors coupled to inositol phospholipid hydrolysis in human detrusor cultured smooth muscle cells. J Urol154: 1241–1245 | Article | PubMed | ISI | ChemPort |
  30. Clemett D and Jarvis B (2001) Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging 18: 277–304 | Article | PubMed | ISI | ChemPort |
  31. Todorova A et al. (2001) Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J Clin Pharmacol 41: 636–644 | Article | PubMed | ISI | ChemPort |
  32. Kornhuber HH and Schutz A (1990) Efficient treatment of neurogenic bladder disorders in multiple sclerosis with initial intermittent catheterization and ultrasound-controlled training. Eur Neurol 30: 260–267 | PubMed | ISI | ChemPort |
  33. Fowler CJ (1996) Investigation of the neurogenic bladder. J Neurol Neurosurg Psychiatry 60: 6–13 | PubMed | ISI | ChemPort |
  34. Fowler CJ et al. (1992) Treatment of lower urinary tract dysfunction in patients with multiple sclerosis. Committee of the European Study Group of SUDIMS (Sexual and Urological Disorders in Multiple Sclerosis). J Neurol Neurosurg Psychiatry 55: 986–989 | PubMed | ISI | ChemPort |
  35. Seland PT et al. (1999) Urinary dysfunction and Multiple Sclerosis. Evidence-Based Management Strategies for Urinary Dysfunction in Multiple Sclerosis. Multiple Sclerosis Council for Clinical Practice Guidelines. Washington DC: PVA Publications
  36. Kaplan SA et al. (1991) Bladder and sphincter behavior in patients with spinal cord lesions. J Urol 146: 113–117 | PubMed | ISI | ChemPort |
  37. Barbalias GA et al. (1998) Vesicourethral dysfunction associated with multiple sclerosis: clinical and urodynamic perspectives. J Urol 160: 106–111 | PubMed | ISI | ChemPort |
  38. Norlen L and Sundin T (1978) Alpha-adrenolytic treatment in patients with autonomous bladders. Acta Pharmacol Toxicol (Copenh) 43 (Suppl 2): S31–S34
  39. O’Riordan JI et al. (1995) Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis? J Urol 153: 1114–1116 | PubMed | ChemPort |
  40. Schwinn DA (2000) Novel role for alpha1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int 86 (Suppl 2): S11–S20 | Article |
  41. Nathan P (1977) Emptying the paralysed bladder. Lancet 1: 377 | PubMed | ISI | ChemPort |
  42. Dasgupta P et al. (1997) The ‘Queen Square bladder stimulator’: a device for assisting emptying of the neurogenic bladder. Br J Urol 80: 234–237 | PubMed | ISI | ChemPort |
  43. Prasad RS et al. (2003) Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehabil 17: 42–47 | Article | PubMed | ISI | ChemPort |
  44. Rew DA and Rundle JS (1989) Assessment of the safety of regular DDAVP therapy in primary nocturnal enuresis. Br J Urol 63: 352–353 | PubMed | ISI | ChemPort |
  45. Hilton P et al. (1983) The use of desmopressin (DDAVP) for nocturia in women with multiple sclerosis. J Neurol Neurosurg Psychiatry 46: 854–855 | PubMed | ISI | ChemPort |
  46. Hoverd PA and Fowler CJ (1998) Desmopressin in the treatment of daytime urinary frequency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 65: 778–780 | PubMed | ISI | ChemPort |
  47. Tubridy N et al. (1999) Long term use of desmopressin for urinary symptoms in multiple sclerosis. Mult Scler 5: 416–417 | Article | PubMed | ISI | ChemPort |
  48. Gades NM et al. (2005) Prevelence of conditions potentially associated with lower urinary tract symptoms in men. BJU Int 95: 554–593 | PubMed |
  49. AUA Practice Guidelines Committee (2003) AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations. J Urol 170: 530–547 | ISI |
  50. House of Lords Committee on Science and Technology (1998) House of Lords Committee on Science and Technology. Cannabis: the scientific and medical evidence (9th report). London: Stationary Office
  51. Brady CM et al. (2004) An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler 10: 425–433 | Article | PubMed | ISI | ChemPort |
  52. Zajicek J et al. (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362: 1517–1526 | Article | PubMed | ISI | ChemPort |
  53. Freeman R et al. (2004) The effect of cannabinoids on lower urinary tract symptoms in multiple sclerosis: a randomised placebo controlled trial (CAMS-LUTS study). Neurourol Urodyn 23: 607 (A149) | ISI | ChemPort |
  54. Fowler CJ et al. (1992) Intravesical capsaicin for neurogenic bladder dysfunction.Lancet 339: 1239 | Article | PubMed | ISI | ChemPort |
  55. de Seze M et al. (1999) Intravesical instillation of capsaicin in urology: A review of the literature. Eur Urol 36: 267–277 | Article | PubMed | ISI | ChemPort |
  56. Appendino G and Szallasi A (1997) Euphorbium: modern research on its active principle, resiniferatoxin, revives an ancient medicine. Life Sci 60: 681–696 | Article | PubMed | ISI | ChemPort |
  57. Giannantoni A et al. (2002) Intravesical capsaicin versus resiniferatoxin in patients with detrusor hyperreflexia: a prospective randomized study. J Urol 167: 1710–1714 | Article | PubMed | ISI | ChemPort |
  58. Cruz F (2002) Vanilloid receptor and detrusor instability. Urology 59 (Suppl 1): S51–S60 | Article |
  59. Brady CM et al. (2004) Parallel changes in bladder suburothelial vanilloid receptor TRPV1 (VR1) and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity (NDO) following intravesical resiniferatoxin treatment. BJU Int 93: 770–776 | Article | PubMed | ISI | ChemPort |
  60. de Seze M et al. (2004) Intravesical capsaicin versus resiniferatoxin for the treatment of detrusor hyperreflexia in spinal cord injured patients: a double-blind, randomized, controlled study. J Urol 171: 251–255 | Article | PubMed | ISI | ChemPort |
  61. Schurch B et al. (2000) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164: 692–697 | Article | PubMed | ISI | ChemPort |
  62. Reitz A et al. (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45: 510–515 | Article | PubMed | ISI | ChemPort |
  63. Apostolidis A et al. (2005) Decreased sensory receptors P2x3 and TRPV1 in suburothealial nerve fibres following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 174: 977–983 | Article | PubMed | ISI | ChemPort |
  64. Popat R et al. (2005) A comparison between the response of patients with idiopathic detrusor overactivity (IDO) and neurogenic detrusor overactivity (NDO) to the first intradetrusor injection of botulinum A toxin. J Urol 174: 984–988 | Article | PubMed | ISI | ChemPort |
  65. Harper M et al. (2003) A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 92: 325–326 | Article | PubMed | ISI | ChemPort |
  66. Kalsi V et al. (2005) A cost consequence model for botulinum toxin-a used in the treatment of 89 patients with detrusor overactivity: preliminary results. Eur Urol4: 104
  67. Chancellor MB and Blaivas JG (1993) Multiple Sclerosis. Probl Urol 7: 15–33
  68. Goldwasser B and Webster GD (1986) Augmentation and substitution enterocystoplasty. J Urol 135: 215–224 | PubMed | ISI | ChemPort |
  69. Luangkhot R et al. (1991) Ileocecocystoplasty for the management of refractory neurogenic bladder: surgical technique and urodynamic findings. J Urol 146: 1340–1344 | PubMed | ISI | ChemPort |
  70. Chartier-Kastler EJ et al. (2000) Long-term results of sacral nerve stimulation (S3) for the treatment of neurogenic refractory urge incontinence related to detrusor hyperreflexia. J Urol 164: 1476–1480 | PubMed | ISI | ChemPort |
  71. Barnes DG et al. (1993) Management of the neuropathic bladder by suprapubic catheterisation. Br J Urol 72: 169–172 | PubMed | ISI | ChemPort |